title: [New drug treatment possibilities in castration resistant prostate carcinoma].
authors.affiliation: Medizinbereich Innere Medizin-Onkologie, Klinik für Onkologie, Universitätsspital Zürich.
authors.forename: A
authors.initials: A
authors.lastname: Meisel
authors.forename: F
authors.initials: F
authors.lastname: Stenner
mesh_terms: D000368:Aged; D059002:Androgen Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008175:Lung Neoplasms / Q000175:diagnosis / Q000556:secondary; D008297:Male; D009919:Orchiectomy; D010166:Palliative Care; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D059002:Androgen Receptor Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D013254:Steroid 17-alpha-Hydroxylase